Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

macregen.com

About Macregen

Macregen is developing transformative therapies for the preservation and treatment of vision in patients suffering from age-related macular degeneration (AMD) and other eye diseases. Macregen and its partners seek to develop, register, and commercialize first-in-class breakthrough drugs, given alone or in combination with other drugs for the treatment of both dry and wet AMD.

Macregen Headquarters Location

4200 The Woods Drive

San Jose, California, 95136,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Macregen Patents

Macregen has filed 6 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Disorders of choroid and retina
  • Ophthalmology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2018

2/2/2021

Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Rare diseases, Complement system

Grant

Application Date

7/17/2018

Grant Date

2/2/2021

Title

Related Topics

Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Rare diseases, Complement system

Status

Grant

Latest Macregen News

VIDEO: When treating AMD, ‘believe the B scans’

Jul 29, 2020

Healio Interview Disclosures: Curcio reports receiving research support from Genentech and Heidelberg Engineering, and is a stockholder with Macregen Inc. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio In this exclusive video, Christine A. Curcio, PhD, White-McKee endowed professor in ophthalmology in the department of ophthalmology and visual sciences at the University of Alabama at Birmingham, explains how hyperreflective foci — which are commonly detected during OCT B scans of patients with age-related macular degeneration — are “huge risk factors for the progression to atrophy.” Using cone and rod mediated vision, Curcio and her lab worked with clinicians to determine if there were “functional correlates to the presence of HRF,” and the findings were presented at this year’s virtual ARVO annual meeting. “We should believe the B scans, they will help us win AMD,” Curcio said. Reference Curcio CA, et al. Hyperreflective foci and specks are associated with delayed rod-mediated dark adaptation in non-neovascular age-related macular degeneration (AMD). Presented at: Association for Research in Vision and Ophthalmology annual meeting; June 12, 2020 (virtual meeting).

  • Where is Macregen's headquarters?

    Macregen's headquarters is located at 4200 The Woods Drive, San Jose.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.